论文部分内容阅读
目的观察奥沙利铂(L-OHP)联合希罗达(Xeloda)在治疗晚期胃癌中的作用。方法 L-OHP130mg/m2,静滴,持续2h,d1;Xeloda2500mg/m2,早晚各服1次,连服14d,21d为1个周期,连用3个周期。结果 32例患者中,CR2例,PR18例,SD9例,PD3例,RR为62.4%,不良反应主要为末梢神经炎、手足综合症、恶心呕吐,患者均可耐受。结论 L-OHP联合希罗达治疗晚期胃癌,疗效高,耐受性好,能显著提高患者生存质量。
Objective To observe the effect of oxaliplatin (L-OHP) combined with Xeloda in the treatment of advanced gastric cancer. Methods L-OHP 130mg/m2, intravenous infusion, continued 2h, d1; Xeloda 2500mg/m2, sooner or later, each serving 1, even served 14d, 21d for 1 cycle, with 3 cycles. Results Of the 32 patients, 2 were CR, 18 were PR, 9 were SD, 3 were PD, and the RR was 62.4%. The adverse reactions were mainly peripheral neuropathy, hand-foot syndrome, nausea and vomiting. All patients were tolerant. Conclusion L-OHP combined with xeloda for the treatment of advanced gastric cancer has high curative effect and good tolerability. It can significantly improve the quality of life of patients.